FULL TEST BANK FOR PHARMACOLOGY A PATIENT-CENTERED NURSING
PROCESS APPROACH 11TH EDITION BY LINDA E. MCCUISTION; JENNIFER J.
YEAGER; MARY B. WINTON;KATHLEEN DIMAGGIO CHAPTER 1-58 COMPLETE
GUIDE A+
,TABLE OF CONTENTS
CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE ...................................... 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS..................................... 11
CHAPTER 03: PHARMACOKINETICS AND PHARMACODYNAMICS ............................................ 22
CHAPTER 04: PHARMACOGENETICS ......................................................................................... 42
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................. 46
CHAPTER 06: PEDIATRIC CONSIDERATIONS .............................................................................. 54
CHAPTER 07: GERIATRIC CONSIDERATIONS.............................................................................. 63
CHAPTER 08: DRUGS IN SUBSTANCE USE DISORDER ................................................................ 71
CHAPTER 09: SAFETY AND QUALITY .......................................................................................... 79
CHAPTER 10: DRUG ADMINISTRATION ..................................................................................... 87
CHAPTER 11: DRUG CALCULATIONS ......................................................................................... 94
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ................................................................. 100
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ........................................................... 113
CHAPTER 14: NUTRITIONAL SUPPORT .................................................................................... 123
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ................................................... 134
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................. 142
CHAPTER 17: STIMULANTS ...................................................................................................... 151
CHAPTER 18: DEPRESSANTS .................................................................................................... 157
CHAPTER 19: ANTISEIZURE DRUGS ......................................................................................... 166
CHAPTER 20: DRUGS FOR PARKINSONISM AND ALZHEIMER DISEASE ................................... 176
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS ................ 186
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS................................................................. 194
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ................................................... 204
CHAPTER 24: ANTIINFLAMMATORIES ..................................................................................... 215
CHAPTER 25: ANALGESICS ....................................................................................................... 224
CHAPTER 26: PENICILLINS, OTHER BETA-LACTAMS, AND CEPHALOSPORINS ........................ 233
CHAPTER 27: MACROLIDES, OXAZOLIDINONES, LINCOSAMIDES, GLYCOPEPTIDES, KETOLIDES,
AND LIPOPEPTIDES .................................................................................................................. 241
CHAPTER 28: TETRACYCLINES, GLYCYLCYCLINES, AMINOGLYCOSIDES, AND
FLUOROQUINOLONES MCCUISTION: ...................................................................................... 246
CHAPTER 29: SULFONAMIDES AND NITROIMIDAZOLES ANTIBIOTICS ................................... 252
,CHAPTER 30: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ..................................... 259
CHAPTER 31: ANTIMALARIALS, ANTHELMINTICS, AND PEPTIDES .......................................... 270
CHAPTER 32: HIV- AND AIDS-RELATED DRUGS ....................................................................... 275
CHAPTER 33: TRANSPLANT DRUGS ......................................................................................... 281
CHAPTER 34: VACCINES........................................................................................................... 284
CHAPTER 35: ANTICANCER DRUGS ......................................................................................... 290
CHAPTER 36: TARGETED THERAPIES TO TREAT CANCER ........................................................ 297
CHAPTER 37: BIOLOGIC RESPONSE MODIFIERS ...................................................................... 302
CHAPTER 38: UPPER RESPIRATORY DISORDERS ..................................................................... 309
CHAPTER 39: LOWER RESPIRATORY DISORDERS .................................................................... 316
CHAPTER 40: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................. 328
CHAPTER 41: DIURETICS .......................................................................................................... 340
CHAPTER 42: ANTIHYPERTENSIVES ......................................................................................... 347
CHAPTER 43: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ........................... 357
CHAPTER 44: ANTIHYPERLIPIDEMICS AND DRUGS TO IMPROVE PERIPHERAL BLOOD FLOW
MCCUISTION: .......................................................................................................................... 369
CHAPTER 45: GASTROINTESTINAL TRACT DISORDERS ............................................................ 377
CHAPTER 46: ANTIULCER DRUGS ............................................................................................ 388
CHAPTER 47: EYE AND EAR DISORDERS .................................................................................. 400
CHAPTER 48: DERMATOLOGIC DISORDERS ............................................................................ 406
CHAPTER 49: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ................... 414
CHAPTER 50: ANTIDIABETICS .................................................................................................. 426
CHAPTER 51: URINARY DISORDERS......................................................................................... 437
CHAPTER 52: PREGNANCY AND PRETERM LABOR .................................................................. 446
CHAPTER 53: LABOR, DELIVERY, AND POSTPARTUM ............................................................. 457
CHAPTER 54: NEONATAL AND NEWBORN .............................................................................. 465
CHAPTER 55: WOMEN’S REPRODUCTIVE HEALTH .................................................................. 469
CHAPTER 56: MEN’S HEALTH AND REPRODUCTIVE DISORDERS ............................................ 479
CHAPTER 57: SEXUALLY TRANSMITTED INFECTIONS .............................................................. 486
CHAPTER 58: ADULT AND PEDIATRIC EMERGENCY DRUGS.................................................... 491
, CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS APPROACH, 11TH
EDITION
MULTIPLE CHOICE
1. ALL OF THE FOLLOWING WOULD BE CONSIDERED SUBJECTIVE DATA, EXCEPT:
A. PATIENT-REPORTED HEALTH HISTORY
B. PATIENT-REPORTED SIGNS AND SYMPTOMS OF THEIR ILLNESS
C. FINANCIAL BARRIERS REPORTED BY THE PATIENT’S CAREGIVER
D. VITAL SIGNS OBTAINED FROM THE MEDICAL RECORD
ANSWER:D
SUBJECTIVE DATA IS BASED ON WHAT PATIENTS OR FAMILY MEMBERS COMMUNICATE TO THE
NURSE. PATIENT- REPORTED HEALTH HISTORY, SIGNS AND SYMPTOMS, AND CAREGIVER
REPORTED FINANCIAL BARRIERS WOULD BE CONSIDERED SUBJECTIVE DATA. VITAL SIGNS
OBTAINED FROM THE MEDICAL RECORD WOULD BE CONSIDERED OBJECTIVE DATA.
2. THE NURSE IS USING DATA COLLECTED TO DEFINE A SET OF INTERVENTIONS TO
ACHIEVE THE MOST DESIRABLE OUTCOMES. WHICH OF THE FOLLOWING STEPS IS THE NURSE
APPLYING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. GENERATE SOLUTIONS (PLANNING)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANSWER:C
WHEN GENERATING SOLUTIONS (PLANNING), THE NURSE IDENTIFIES EXPECTED OUTCOMES
AND USES THE PATIENT’S PROBLEM(S) TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE
PROCESS APPROACH 11TH EDITION BY LINDA E. MCCUISTION; JENNIFER J.
YEAGER; MARY B. WINTON;KATHLEEN DIMAGGIO CHAPTER 1-58 COMPLETE
GUIDE A+
,TABLE OF CONTENTS
CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE ...................................... 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS..................................... 11
CHAPTER 03: PHARMACOKINETICS AND PHARMACODYNAMICS ............................................ 22
CHAPTER 04: PHARMACOGENETICS ......................................................................................... 42
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................. 46
CHAPTER 06: PEDIATRIC CONSIDERATIONS .............................................................................. 54
CHAPTER 07: GERIATRIC CONSIDERATIONS.............................................................................. 63
CHAPTER 08: DRUGS IN SUBSTANCE USE DISORDER ................................................................ 71
CHAPTER 09: SAFETY AND QUALITY .......................................................................................... 79
CHAPTER 10: DRUG ADMINISTRATION ..................................................................................... 87
CHAPTER 11: DRUG CALCULATIONS ......................................................................................... 94
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ................................................................. 100
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ........................................................... 113
CHAPTER 14: NUTRITIONAL SUPPORT .................................................................................... 123
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ................................................... 134
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................. 142
CHAPTER 17: STIMULANTS ...................................................................................................... 151
CHAPTER 18: DEPRESSANTS .................................................................................................... 157
CHAPTER 19: ANTISEIZURE DRUGS ......................................................................................... 166
CHAPTER 20: DRUGS FOR PARKINSONISM AND ALZHEIMER DISEASE ................................... 176
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS ................ 186
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS................................................................. 194
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ................................................... 204
CHAPTER 24: ANTIINFLAMMATORIES ..................................................................................... 215
CHAPTER 25: ANALGESICS ....................................................................................................... 224
CHAPTER 26: PENICILLINS, OTHER BETA-LACTAMS, AND CEPHALOSPORINS ........................ 233
CHAPTER 27: MACROLIDES, OXAZOLIDINONES, LINCOSAMIDES, GLYCOPEPTIDES, KETOLIDES,
AND LIPOPEPTIDES .................................................................................................................. 241
CHAPTER 28: TETRACYCLINES, GLYCYLCYCLINES, AMINOGLYCOSIDES, AND
FLUOROQUINOLONES MCCUISTION: ...................................................................................... 246
CHAPTER 29: SULFONAMIDES AND NITROIMIDAZOLES ANTIBIOTICS ................................... 252
,CHAPTER 30: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ..................................... 259
CHAPTER 31: ANTIMALARIALS, ANTHELMINTICS, AND PEPTIDES .......................................... 270
CHAPTER 32: HIV- AND AIDS-RELATED DRUGS ....................................................................... 275
CHAPTER 33: TRANSPLANT DRUGS ......................................................................................... 281
CHAPTER 34: VACCINES........................................................................................................... 284
CHAPTER 35: ANTICANCER DRUGS ......................................................................................... 290
CHAPTER 36: TARGETED THERAPIES TO TREAT CANCER ........................................................ 297
CHAPTER 37: BIOLOGIC RESPONSE MODIFIERS ...................................................................... 302
CHAPTER 38: UPPER RESPIRATORY DISORDERS ..................................................................... 309
CHAPTER 39: LOWER RESPIRATORY DISORDERS .................................................................... 316
CHAPTER 40: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................. 328
CHAPTER 41: DIURETICS .......................................................................................................... 340
CHAPTER 42: ANTIHYPERTENSIVES ......................................................................................... 347
CHAPTER 43: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ........................... 357
CHAPTER 44: ANTIHYPERLIPIDEMICS AND DRUGS TO IMPROVE PERIPHERAL BLOOD FLOW
MCCUISTION: .......................................................................................................................... 369
CHAPTER 45: GASTROINTESTINAL TRACT DISORDERS ............................................................ 377
CHAPTER 46: ANTIULCER DRUGS ............................................................................................ 388
CHAPTER 47: EYE AND EAR DISORDERS .................................................................................. 400
CHAPTER 48: DERMATOLOGIC DISORDERS ............................................................................ 406
CHAPTER 49: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ................... 414
CHAPTER 50: ANTIDIABETICS .................................................................................................. 426
CHAPTER 51: URINARY DISORDERS......................................................................................... 437
CHAPTER 52: PREGNANCY AND PRETERM LABOR .................................................................. 446
CHAPTER 53: LABOR, DELIVERY, AND POSTPARTUM ............................................................. 457
CHAPTER 54: NEONATAL AND NEWBORN .............................................................................. 465
CHAPTER 55: WOMEN’S REPRODUCTIVE HEALTH .................................................................. 469
CHAPTER 56: MEN’S HEALTH AND REPRODUCTIVE DISORDERS ............................................ 479
CHAPTER 57: SEXUALLY TRANSMITTED INFECTIONS .............................................................. 486
CHAPTER 58: ADULT AND PEDIATRIC EMERGENCY DRUGS.................................................... 491
, CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS APPROACH, 11TH
EDITION
MULTIPLE CHOICE
1. ALL OF THE FOLLOWING WOULD BE CONSIDERED SUBJECTIVE DATA, EXCEPT:
A. PATIENT-REPORTED HEALTH HISTORY
B. PATIENT-REPORTED SIGNS AND SYMPTOMS OF THEIR ILLNESS
C. FINANCIAL BARRIERS REPORTED BY THE PATIENT’S CAREGIVER
D. VITAL SIGNS OBTAINED FROM THE MEDICAL RECORD
ANSWER:D
SUBJECTIVE DATA IS BASED ON WHAT PATIENTS OR FAMILY MEMBERS COMMUNICATE TO THE
NURSE. PATIENT- REPORTED HEALTH HISTORY, SIGNS AND SYMPTOMS, AND CAREGIVER
REPORTED FINANCIAL BARRIERS WOULD BE CONSIDERED SUBJECTIVE DATA. VITAL SIGNS
OBTAINED FROM THE MEDICAL RECORD WOULD BE CONSIDERED OBJECTIVE DATA.
2. THE NURSE IS USING DATA COLLECTED TO DEFINE A SET OF INTERVENTIONS TO
ACHIEVE THE MOST DESIRABLE OUTCOMES. WHICH OF THE FOLLOWING STEPS IS THE NURSE
APPLYING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. GENERATE SOLUTIONS (PLANNING)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANSWER:C
WHEN GENERATING SOLUTIONS (PLANNING), THE NURSE IDENTIFIES EXPECTED OUTCOMES
AND USES THE PATIENT’S PROBLEM(S) TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE
